Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

被引:76
|
作者
Makita, Shinichi [1 ]
Yoshimura, Kiyoshi [2 ,3 ]
Tobinai, Kensei [1 ]
机构
[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[3] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Tokyo, Japan
关键词
Adoptive cell therapy; B-cell non-Hodgkin lymphoma; CAR T; CD19; chimeric antigen receptor; CYTOKINE-RELEASE SYNDROME; LYMPHOBLASTIC-LEUKEMIA; CD19; CTL019; REMISSIONS; TOXICITY; MALIGNANCIES; MULTICENTER; LYMPHOCYTES; ACTIVATION; EXPERIENCE;
D O I
10.1111/cas.13239
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
B-cell non-Hodgkin lymphoma (B-NHL) is the most frequent hematological malignancy. Although refined chemotherapy regimens and several new therapeutics including rituximab, a chimeric anti-CD20 monoclonal antibody, have improved its prognosis in recent decades, there are still a substantial number of patients with chemorefractory B-NHL. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is expected to be an effective adoptive cell treatment and has the potential to overcome the chemorefractoriness of B-cell leukemia and lymphoma. Recently, several clinical trials have shown remarkable efficacy of anti-CD19 CAR T-cell therapy, not only in B-acute lymphoblastic leukemia but also in B-NHL. Nonetheless, there are several challenges to overcome before introduction into clinical practice, such as: (i) further refinement of the manufacturing process, (ii) further improvement of efficacy, (iii) finding the optimal infusion cell dose, (iv) optimization of lymphocyte-depleting chemotherapy, (v) identification of the best CAR structure, and (vi) optimization of toxicity management including cytokine release syndrome, neurologic toxicity, and on-target off-tumor toxicity. Several ways to solve these problems are currently under study. In this review, we describe the updated clinical data regarding anti-CD19 CAR T-cell therapy, with a focus on B-NHL, and discuss the clinical implications and perspectives of CAR T-cell therapy.
引用
收藏
页码:1109 / 1118
页数:10
相关论文
共 50 条
  • [31] Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
    Tan, Brendan Jen-Wei
    Chan, Ling-Ling
    Tan, Eng-King
    NEUROLOGY, 2023, 100 (14)
  • [32] Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist
    Jacobson, Caron A.
    Farooq, Umar
    Ghobadi, Armin
    ONCOLOGIST, 2020, 25 (01): : E138 - E146
  • [33] Editors' Note: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
    Lewis, Ariane
    Galetta, Steven
    NEUROLOGY, 2023, 100 (14)
  • [34] Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
    Hamilton, Mark P.
    Miklos, David B.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1053 - 1075
  • [35] Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
    Zhou, Wenyujing
    Chen, Weihong
    Wan, Xiaochun
    Luo, Changru
    Du, Xin
    Li, Xiaoqing
    Chen, Qian
    Gao, Ruiwen
    Zhang, Xiaohan
    Xie, Mei
    Wang, Mingjun
    FRONTIERS IN GENETICS, 2022, 12
  • [36] Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy
    Crombie, Jennifer L.
    Jacobson, Caron A.
    Redd, Robert
    Shouse, Geoffrey
    Herrera, Alex F.
    Chow, Victor A.
    Gauthier, Jordan
    Mullane, Erin
    Cahill, Kirk
    Kline, Justin
    Romancik, Jason
    Cohen, Jonathon B.
    Saucier, Anna
    Houot, Roch
    Armand, Philippe
    Hess, Brian
    REVISTA CHILENA DE LITERATURA, 2023, (108): : 3433 - 3437
  • [37] Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
    Roy, Ishan
    Smilnak, Gordon
    Burkart, Madelyn
    Hamilton, Elizabeth
    Thorp, Katherine
    Miyata, Sarah
    Ma, Shuo
    Pro, Barbara
    Winter, Jane
    Gordon, Leo
    Karmali, Reem
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (01) : 71 - 75
  • [38] Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products
    Hunter, Bradley D.
    Rogalski, Michael
    Jacobson, Caron A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1157 - 1164
  • [39] Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
    Chong, Elise A.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Landsburg, Daniel J.
    Winchell, Nicole
    Napier, Ellen
    Mato, Anthony R.
    Melenhorst, J. Joseph
    Ruella, Marco
    Lacey, Simon F.
    June, Carl H.
    Schuster, Stephen J.
    BLOOD, 2018, 132
  • [40] Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia
    Liu, Y.
    Chen, X.
    Han, W.
    Zhang, Y.
    DRUGS OF TODAY, 2017, 53 (11) : 597 - 608